Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention

Contents

[1]  Beverley Balkau,et al.  Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. , 2003, Diabetes care.

[2]  Jaakko Tuomilehto,et al.  The diabetes risk score: a practical tool to predict type 2 diabetes risk. , 2003, Diabetes care.

[3]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[4]  G. Gallus,et al.  Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. , 2003, Diabetes care.

[5]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[6]  S. Haffner,et al.  Predicting Impaired Glucose Tolerance (IGT) among Individuals with a Non-Diabetic Fasting Glucose Value: The San Antonio Heart Study , 2002 .

[7]  Robert Atkins,et al.  The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. , 2002, Diabetes care.

[8]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[9]  B. Rajendran.  Impaired fasting glucose versus impaired glucose tolerance. , 2001, The Journal of the Association of Physicians of India.

[10]  B. Howard,et al.  Diabetes and cardiovascular disease , 2000, Annual review of medicine.

[11]  J. M. Quesada-Gomez,et al.  Nonhypoglycemic effects of thiazolidinediones. , 2001, Annals of internal medicine.

[12]  W. Thompson.  Early recognition and treatment of glucose abnormalities to prevent type 2 diabetes mellitus and coronary heart disease. , 2001, Mayo Clinic proceedings.

[13]  B. Balkau,et al.  Reproducibility of the diagnosis of diabetes over a 30-month follow-up: the Paris Prospective Study. , 2001, Diabetes care.

[14]  J. Price,et al.  Interactions of impaired glucose transport and phosphorylation in skeletal muscle insulin resistance: a dose-response assessment using positron emission tomography. , 2001, Diabetes.

[15]  T. Buchanan,et al.  Protection from Type 2 Diabetes Persists in the TRIPOD Cohort Eight Months after Stopping Troglitazone , 2001 .

[16]  A. Scheen,et al.  Thiazolidinediones and liver toxicity. , 2001, Diabetes & metabolism.

[17]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[18]  P W Macfarlane,et al.  Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.

[19]  N. Wareham,et al.  Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) , 2001, BMJ : British Medical Journal.

[20]  E. Feskens,et al.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.

[21]  M. Hanefeld,et al.  Post‐challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima‐media thickness: the RIAD Study , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[22]  J. Tuomilehto,et al.  Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts , 2000, Diabetologia.

[23]  R. Kawamori,et al.  Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue. , 2000, Endocrine journal.

[24]  R. Hanson,et al.  Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. , 2000, Diabetes care.

[25]  R. Hanson,et al.  The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. , 2000, Diabetes care.

[26]  R. Dina,et al.  Angiotensin II-receptor antagonists: an overview. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[27]  M. Davies,et al.  Impaired glucose tolerance and fasting hyperglycaemia have different characteristics , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[28]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[29]  C. Bogardus,et al.  Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. , 1999, Diabetes.

[30]  W. Rathmann,et al.  Cardiovascular risk factors in newly diagnosed abnormal glucose tolerance: comparison of 1997 ADA and 1985 WHO criteria , 1999, Diabetologia.

[31]  G. Riccardi,et al.  Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis. , 1999, Diabetes care.

[32]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[33]  R. DeFronzo.  Pharmacologic Therapy for Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[34]  L. Bouter,et al.  Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study , 1999, Diabetologia.

[35]  J. Sowers,et al.  Diabetes and cardiovascular disease. , 1999, Diabetes care.

[36]  J Tuomilehto,et al.  Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? , 1999, Diabetes care.

[37]  M. Hanefeld,et al.  Impaired fasting glucose is not a risk factor for atherosclerosis , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[38]  S. Yusuf,et al.  The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.

[39]  E. Feskens,et al.  Performance of a predictive model to identify undiagnosed diabetes in a health care setting. , 1999, Diabetes care.

[40]  N. Day,et al.  Fasting proinsulin concentrations predict the development of type 2 diabetes. , 1999, Diabetes care.

[41]  J. Chan,et al.  Use of the 1997 American Diabetes Association Diagnostic Criteria for Diabetes in a Hong Kong Chinese Population , 1998, Diabetes Care.

[42]  S. Gimeno,et al.  Comparison of glucose tolerance categories according to World Health Organization and American Diabetes Association diagnostic criteria in a population-based study in Brazil. The Japanese-Brazilian Diabetes Study Group. , 1998, Diabetes care.

[43]  M. Laakso,et al.  The STOP-NIDDM Trial: An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data , 1998, Diabetes Care.

[44]  L. Bouter,et al.  The 1997 American Diabetes Association Criteria Versus the 1985 World Health Organization Criteria for the Diagnosis of Abnormal Glucose Tolerance: Poor agreement in the Hoorn Study , 1998, Diabetes Care.

[45]  G. Berglund,et al.  Comparison of ADA and WHO criteria for diagnosis of diabetes and glucose intolerance , 1998, Diabetologia.

[46]  H. Lithell,et al.  Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data , 1998 .

[47]  B. Ahrén,et al.  Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine , 1998, Diabetologia.

[48]  T. Buchanan,et al.  TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. , 1998, Controlled clinical trials.

[49]  M. Laakso,et al.  The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. , 1998, Diabetes care.

[50]  K. Flegal,et al.  Comparison of Diabetes Diagnostic Categories in the U.S. Population According to 1997 American Diabetes Association and 1980–1985 World Health Organization Diagnostic Criteria , 1997, Diabetes Care.

[51]  A. Motala,et al.  Transient Impaired Glucose Tolerance in South African Indians Does Not Carry a Risk for Progression to NIDDM , 1997, Diabetes Care.

[52]  L. Bouter,et al.  Performance of an NIDDM Screening Questionnaire Based on Symptoms and Risk Factors , 1997, Diabetes Care.

[53]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[54]  M. Safar,et al.  The Effect of Metformin on the Metabolic Abnormalities Associated With Upper-Body Fat Distribution. BIGPRO Study Group , 1996, Diabetes Care.

[55]  M. Stern.  Diabetes and Cardiovascular Disease: The “Common Soil” Hypothesis , 1995, Diabetes.

[56]  S. Haffner,et al.  Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? , 1990, JAMA.

[57]  P. Bennett,et al.  Transient impaired glucose tolerance in Pima Indians: is it important? , 1988, BMJ.

[58]  G Rose,et al.  Sick individuals and sick populations. , 1985, International journal of epidemiology.

[59]  W. Reitsma,et al.  [WHO Expert Committee on diabetes mellitus]. , 1981, Nederlands tijdschrift voor geneeskunde.

[60]  Dang Qing,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance The , 2022 .